ANVS biotech catalysts & pipeline

ANNOVIS BIO INC · Data as of 2026-09-08

Upcoming catalysts

buntanetap — Topline data

Q1 2027

The Company plans a database lock for the 6-month analysis in Q1 2027, with the top-line symptomatic data readout anticipated in the same quarter.

Source filing

buntanetap — NDA/BLA submission

early 2027

New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028

Source filing

buntanetap — NDA/BLA submission

early 2028

New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028

Source filing

Explore the free biotech catalyst calendar